 William Robinson
Concepts (850)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Melanoma | 93 | 2024 | 762 | 6.960 |
Why?
| | Skin Neoplasms | 49 | 2025 | 849 | 3.930 |
Why?
| | Proto-Oncogene Proteins c-kit | 6 | 2019 | 68 | 1.680 |
Why?
| | Mastocytosis | 3 | 2021 | 12 | 1.450 |
Why?
| | Antineoplastic Agents | 19 | 2024 | 2128 | 1.120 |
Why?
| | Spinal Fusion | 4 | 2022 | 252 | 0.920 |
Why?
| | Melanocytes | 7 | 2024 | 65 | 0.870 |
Why?
| | Oncogene Proteins, Fusion | 3 | 2025 | 206 | 0.810 |
Why?
| | Mutation | 17 | 2022 | 3991 | 0.780 |
Why?
| | Vitiligo | 5 | 2024 | 42 | 0.750 |
Why?
| | Antibodies, Monoclonal | 7 | 2018 | 1425 | 0.750 |
Why?
| | Osteoporotic Fractures | 2 | 2020 | 61 | 0.740 |
Why?
| | Thoracic Vertebrae | 2 | 2020 | 76 | 0.740 |
Why?
| | Mucous Membrane | 2 | 2024 | 125 | 0.710 |
Why?
| | Proto-Oncogene Proteins B-raf | 7 | 2025 | 222 | 0.710 |
Why?
| | Mastocytosis, Cutaneous | 1 | 2021 | 5 | 0.690 |
Why?
| | Piperazines | 7 | 2018 | 343 | 0.680 |
Why?
| | Gastrointestinal Stromal Tumors | 2 | 2019 | 38 | 0.650 |
Why?
| | Middle Aged | 94 | 2024 | 33441 | 0.630 |
Why?
| | Spinal Fractures | 1 | 2020 | 74 | 0.620 |
Why?
| | Germ-Line Mutation | 2 | 2019 | 171 | 0.600 |
Why?
| | Exome | 2 | 2017 | 234 | 0.600 |
Why?
| | Humans | 210 | 2025 | 137601 | 0.600 |
Why?
| | Esophageal Achalasia | 1 | 2019 | 28 | 0.590 |
Why?
| | Intervertebral Disc Displacement | 1 | 2019 | 40 | 0.580 |
Why?
| | Neurofibromin 1 | 2 | 2017 | 26 | 0.570 |
Why?
| | Histiocytosis, Sinus | 1 | 2018 | 8 | 0.570 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p16 | 5 | 2013 | 67 | 0.570 |
Why?
| | Humeral Head | 1 | 2017 | 15 | 0.560 |
Why?
| | Osteoporosis | 2 | 2020 | 244 | 0.550 |
Why?
| | Orthopedics | 1 | 2020 | 153 | 0.550 |
Why?
| | Carcinoma, Merkel Cell | 2 | 2008 | 16 | 0.540 |
Why?
| | Arthroplasty, Replacement, Shoulder | 1 | 2017 | 34 | 0.540 |
Why?
| | Skin Pigmentation | 4 | 2024 | 49 | 0.530 |
Why?
| | Intention | 1 | 2019 | 173 | 0.530 |
Why?
| | Genetic Predisposition to Disease | 5 | 2019 | 2365 | 0.530 |
Why?
| | Myeloid-Derived Suppressor Cells | 3 | 2024 | 67 | 0.520 |
Why?
| | RNA Splicing Factors | 1 | 2017 | 55 | 0.520 |
Why?
| | Female | 119 | 2025 | 73359 | 0.510 |
Why?
| | Databases, Factual | 4 | 2020 | 1382 | 0.510 |
Why?
| | Granulocytes | 26 | 1988 | 85 | 0.510 |
Why?
| | Hematopoiesis | 24 | 1988 | 193 | 0.500 |
Why?
| | MicroRNAs | 4 | 2023 | 676 | 0.490 |
Why?
| | Forecasting | 2 | 2017 | 383 | 0.490 |
Why?
| | Ultraviolet Therapy | 4 | 2024 | 16 | 0.480 |
Why?
| | Shoulder Joint | 1 | 2017 | 177 | 0.470 |
Why?
| | Sentinel Lymph Node Biopsy | 7 | 2021 | 113 | 0.470 |
Why?
| | Adult | 95 | 2025 | 37910 | 0.470 |
Why?
| | Osteoarthritis | 1 | 2017 | 200 | 0.460 |
Why?
| | Biomarkers, Tumor | 8 | 2019 | 1233 | 0.460 |
Why?
| | Neoplasms, Second Primary | 3 | 2023 | 112 | 0.450 |
Why?
| | Male | 101 | 2025 | 67690 | 0.450 |
Why?
| | Phosphoproteins | 1 | 2017 | 340 | 0.450 |
Why?
| | Pyrimidines | 4 | 2008 | 462 | 0.450 |
Why?
| | Aged | 63 | 2024 | 23938 | 0.440 |
Why?
| | Aged, 80 and over | 21 | 2021 | 7609 | 0.430 |
Why?
| | Colony-Stimulating Factors | 20 | 1988 | 37 | 0.420 |
Why?
| | Cell Line, Tumor | 18 | 2024 | 3400 | 0.410 |
Why?
| | Microphthalmia-Associated Transcription Factor | 3 | 2008 | 14 | 0.410 |
Why?
| | Nevus | 3 | 2010 | 26 | 0.400 |
Why?
| | Milk, Human | 1 | 2014 | 151 | 0.380 |
Why?
| | Neoplastic Stem Cells | 5 | 2018 | 398 | 0.380 |
Why?
| | Military Personnel | 1 | 2019 | 543 | 0.370 |
Why?
| | Proto-Oncogene Proteins c-ret | 1 | 2012 | 34 | 0.370 |
Why?
| | Pyrroles | 3 | 2021 | 211 | 0.360 |
Why?
| | Myeloid Cell Leukemia Sequence 1 Protein | 3 | 2024 | 41 | 0.350 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 11 | 2023 | 1706 | 0.350 |
Why?
| | Triazines | 2 | 2021 | 43 | 0.350 |
Why?
| | Breast Neoplasms | 8 | 2017 | 2270 | 0.340 |
Why?
| | Gene Expression Regulation, Neoplastic | 6 | 2018 | 1385 | 0.340 |
Why?
| | Sulfonamides | 4 | 2020 | 508 | 0.330 |
Why?
| | Lymph Node Excision | 5 | 2021 | 168 | 0.330 |
Why?
| | Gastrointestinal Neoplasms | 2 | 2008 | 75 | 0.330 |
Why?
| | Sentinel Lymph Node | 2 | 2021 | 44 | 0.330 |
Why?
| | Lymphatic Metastasis | 7 | 2013 | 323 | 0.330 |
Why?
| | Adenocarcinoma | 5 | 2016 | 881 | 0.320 |
Why?
| | Genes, p16 | 3 | 2007 | 17 | 0.320 |
Why?
| | Lumbar Vertebrae | 3 | 2022 | 246 | 0.310 |
Why?
| | High-Throughput Nucleotide Sequencing | 3 | 2018 | 541 | 0.300 |
Why?
| | RNA, Neoplasm | 2 | 2008 | 79 | 0.300 |
Why?
| | Leukocytes | 14 | 1986 | 307 | 0.300 |
Why?
| | Immunohistochemistry | 6 | 2019 | 1718 | 0.290 |
Why?
| | Lumbosacral Region | 2 | 2019 | 60 | 0.290 |
Why?
| | Antineoplastic Agents, Immunological | 2 | 2022 | 190 | 0.290 |
Why?
| | Treatment Outcome | 15 | 2022 | 10813 | 0.290 |
Why?
| | Sarcoma, Clear Cell | 1 | 2008 | 10 | 0.290 |
Why?
| | Tumor Suppressor Proteins | 4 | 2024 | 323 | 0.280 |
Why?
| | Lymphoma, Mantle-Cell | 1 | 2008 | 21 | 0.280 |
Why?
| | Quality Improvement | 2 | 2018 | 1180 | 0.280 |
Why?
| | Cyclins | 1 | 2008 | 92 | 0.280 |
Why?
| | Pyrazoles | 2 | 2021 | 421 | 0.280 |
Why?
| | Proto-Oncogene Proteins | 3 | 2018 | 623 | 0.280 |
Why?
| | Nitrophenols | 3 | 2017 | 34 | 0.280 |
Why?
| | Tretinoin | 4 | 2023 | 122 | 0.270 |
Why?
| | Receptor, Platelet-Derived Growth Factor alpha | 1 | 2008 | 44 | 0.270 |
Why?
| | Biphenyl Compounds | 3 | 2017 | 63 | 0.270 |
Why?
| | Tamoxifen | 3 | 2016 | 201 | 0.260 |
Why?
| | Cell Transformation, Neoplastic | 3 | 2018 | 328 | 0.260 |
Why?
| | Prognosis | 14 | 2024 | 3966 | 0.260 |
Why?
| | Neoplastic Syndromes, Hereditary | 1 | 2007 | 43 | 0.250 |
Why?
| | GTP Phosphohydrolases | 4 | 2020 | 92 | 0.250 |
Why?
| | Interferon-alpha | 6 | 2006 | 201 | 0.240 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 5 | 2021 | 235 | 0.240 |
Why?
| | Arthroplasty, Replacement, Knee | 2 | 2022 | 362 | 0.240 |
Why?
| | Hair Color | 2 | 2024 | 15 | 0.240 |
Why?
| | Xenograft Model Antitumor Assays | 6 | 2018 | 864 | 0.230 |
Why?
| | Nevus, Pigmented | 1 | 2025 | 34 | 0.230 |
Why?
| | DNA, Neoplasm | 5 | 2017 | 157 | 0.230 |
Why?
| | Liposarcoma | 1 | 2005 | 28 | 0.230 |
Why?
| | Follow-Up Studies | 12 | 2020 | 5121 | 0.230 |
Why?
| | Epidermis | 2 | 2024 | 156 | 0.230 |
Why?
| | T-Lymphocytes, Regulatory | 3 | 2023 | 388 | 0.220 |
Why?
| | Intestinal Neoplasms | 1 | 2024 | 30 | 0.220 |
Why?
| | Intestine, Small | 2 | 2024 | 155 | 0.220 |
Why?
| | Polymerase Chain Reaction | 6 | 2008 | 1047 | 0.220 |
Why?
| | Ultraviolet Rays | 4 | 2024 | 397 | 0.220 |
Why?
| | Dasatinib | 1 | 2024 | 54 | 0.220 |
Why?
| | Hyperpigmentation | 1 | 2024 | 27 | 0.210 |
Why?
| | Lymph Nodes | 1 | 2006 | 493 | 0.210 |
Why?
| | Piperidines | 2 | 2018 | 206 | 0.210 |
Why?
| | Mice | 28 | 2024 | 17748 | 0.210 |
Why?
| | Dacarbazine | 7 | 2012 | 96 | 0.210 |
Why?
| | Neoplasm Staging | 10 | 2019 | 1359 | 0.210 |
Why?
| | Genomics | 4 | 2024 | 803 | 0.210 |
Why?
| | Burns | 7 | 1997 | 335 | 0.210 |
Why?
| | Hair Follicle | 3 | 2020 | 46 | 0.210 |
Why?
| | Exons | 3 | 2019 | 353 | 0.210 |
Why?
| | Mice, Nude | 4 | 2020 | 688 | 0.210 |
Why?
| | Melatonin | 3 | 1994 | 155 | 0.200 |
Why?
| | Stem Cells | 4 | 2017 | 597 | 0.200 |
Why?
| | Flavonoids | 1 | 2003 | 84 | 0.200 |
Why?
| | HLA-DR Antigens | 2 | 2022 | 228 | 0.200 |
Why?
| | Genes, erbB-1 | 2 | 2016 | 18 | 0.200 |
Why?
| | Lysophospholipids | 1 | 2023 | 80 | 0.190 |
Why?
| | Drug Resistance, Neoplasm | 6 | 2016 | 793 | 0.190 |
Why?
| | Retrospective Studies | 17 | 2025 | 15720 | 0.190 |
Why?
| | Chromosome Aberrations | 2 | 1994 | 157 | 0.190 |
Why?
| | Pedigree | 3 | 2024 | 511 | 0.190 |
Why?
| | Cervical Vertebrae | 2 | 2021 | 140 | 0.190 |
Why?
| | Molecular Targeted Therapy | 3 | 2024 | 408 | 0.190 |
Why?
| | Colonic Neoplasms | 1 | 2024 | 249 | 0.190 |
Why?
| | Lordosis | 1 | 2022 | 16 | 0.190 |
Why?
| | Spondylolisthesis | 1 | 2021 | 8 | 0.190 |
Why?
| | Hematopoietic Stem Cells | 11 | 1986 | 408 | 0.190 |
Why?
| | Mastocytosis, Systemic | 1 | 2021 | 8 | 0.180 |
Why?
| | Clone Cells | 7 | 2010 | 263 | 0.180 |
Why?
| | Registries | 3 | 2020 | 2043 | 0.180 |
Why?
| | Spinal Cord Diseases | 1 | 2021 | 43 | 0.180 |
Why?
| | Neoplasm Recurrence, Local | 9 | 2016 | 1038 | 0.180 |
Why?
| | Cell Cycle Proteins | 3 | 2007 | 614 | 0.170 |
Why?
| | Risk Factors | 8 | 2020 | 10319 | 0.170 |
Why?
| | Gene Expression Profiling | 5 | 2024 | 1752 | 0.170 |
Why?
| | Interleukin-1 | 2 | 2019 | 964 | 0.170 |
Why?
| | Animals | 34 | 2024 | 37088 | 0.170 |
Why?
| | Sonication | 1 | 2020 | 12 | 0.170 |
Why?
| | Drug Therapy, Combination | 5 | 2016 | 1036 | 0.170 |
Why?
| | Turner Syndrome | 1 | 2001 | 52 | 0.160 |
Why?
| | Leukemia | 8 | 1988 | 241 | 0.160 |
Why?
| | CD8-Positive T-Lymphocytes | 2 | 2024 | 912 | 0.160 |
Why?
| | Adult Stem Cells | 1 | 2020 | 40 | 0.160 |
Why?
| | Laser Capture Microdissection | 2 | 2017 | 32 | 0.160 |
Why?
| | Transcription, Genetic | 5 | 2017 | 1455 | 0.160 |
Why?
| | Tissue Culture Techniques | 1 | 2020 | 82 | 0.160 |
Why?
| | Arthroplasty, Replacement, Finger | 1 | 2019 | 3 | 0.160 |
Why?
| | Aniline Compounds | 1 | 2020 | 102 | 0.160 |
Why?
| | Tumor Cells, Cultured | 6 | 2003 | 945 | 0.160 |
Why?
| | Finger Joint | 1 | 2019 | 10 | 0.160 |
Why?
| | Finger Phalanges | 1 | 2019 | 10 | 0.150 |
Why?
| | MAP Kinase Kinase 1 | 1 | 2019 | 75 | 0.150 |
Why?
| | beta Catenin | 2 | 2020 | 252 | 0.150 |
Why?
| | Heart Neoplasms | 2 | 1999 | 52 | 0.150 |
Why?
| | Nomograms | 1 | 2019 | 55 | 0.150 |
Why?
| | Prosthesis-Related Infections | 1 | 2020 | 98 | 0.150 |
Why?
| | Sequence Analysis, RNA | 3 | 2018 | 451 | 0.150 |
Why?
| | Visual Analog Scale | 1 | 2019 | 34 | 0.150 |
Why?
| | RNA | 2 | 2016 | 926 | 0.150 |
Why?
| | Bone Density | 2 | 2020 | 489 | 0.150 |
Why?
| | Prostheses and Implants | 1 | 2020 | 141 | 0.150 |
Why?
| | Signal Transduction | 7 | 2023 | 5060 | 0.150 |
Why?
| | c-Mer Tyrosine Kinase | 1 | 2018 | 41 | 0.150 |
Why?
| | CDC2 Protein Kinase | 1 | 2018 | 31 | 0.150 |
Why?
| | Reoperation | 2 | 2019 | 579 | 0.150 |
Why?
| | Intervertebral Disc Degeneration | 1 | 2019 | 33 | 0.150 |
Why?
| | Ipilimumab | 1 | 2018 | 33 | 0.140 |
Why?
| | SOXB1 Transcription Factors | 1 | 2018 | 62 | 0.140 |
Why?
| | Septins | 1 | 2018 | 43 | 0.140 |
Why?
| | Case-Control Studies | 5 | 2022 | 3550 | 0.140 |
Why?
| | Hospital Costs | 1 | 2018 | 118 | 0.140 |
Why?
| | Leukemia, Myeloid | 10 | 1984 | 47 | 0.140 |
Why?
| | Zinc Finger Protein GLI1 | 1 | 2017 | 25 | 0.140 |
Why?
| | Adolescent | 35 | 2025 | 21435 | 0.140 |
Why?
| | Receptors, Androgen | 1 | 1998 | 149 | 0.140 |
Why?
| | Imatinib Mesylate | 2 | 2008 | 73 | 0.140 |
Why?
| | Biofilms | 1 | 2020 | 264 | 0.140 |
Why?
| | Colony-Forming Units Assay | 19 | 1988 | 96 | 0.140 |
Why?
| | Bone Marrow Cells | 17 | 1983 | 322 | 0.130 |
Why?
| | Burns, Electric | 3 | 1986 | 25 | 0.130 |
Why?
| | Microtubule-Associated Proteins | 1 | 2018 | 195 | 0.130 |
Why?
| | Low Back Pain | 1 | 2019 | 106 | 0.130 |
Why?
| | Bone Marrow | 14 | 1983 | 299 | 0.130 |
Why?
| | Secondary Prevention | 1 | 2018 | 233 | 0.130 |
Why?
| | Databases, Genetic | 1 | 2018 | 241 | 0.130 |
Why?
| | Cisplatin | 4 | 2006 | 325 | 0.130 |
Why?
| | Cancer-Associated Fibroblasts | 1 | 2016 | 19 | 0.130 |
Why?
| | Benzamides | 2 | 2008 | 206 | 0.130 |
Why?
| | Membrane Proteins | 4 | 2020 | 1152 | 0.130 |
Why?
| | Freezing | 4 | 2014 | 88 | 0.130 |
Why?
| | Preservation, Biological | 3 | 2014 | 8 | 0.130 |
Why?
| | Pain Measurement | 1 | 2019 | 527 | 0.130 |
Why?
| | Adenine | 1 | 2018 | 299 | 0.120 |
Why?
| | Genes, Tumor Suppressor | 1 | 1996 | 80 | 0.120 |
Why?
| | Bone Marrow Transplantation | 10 | 1986 | 288 | 0.120 |
Why?
| | Carrier Proteins | 2 | 2000 | 736 | 0.120 |
Why?
| | Mitochondrial Proteins | 1 | 2018 | 257 | 0.120 |
Why?
| | Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 3 | 1994 | 117 | 0.120 |
Why?
| | Drug Synergism | 4 | 2018 | 369 | 0.120 |
Why?
| | Protein Isoforms | 1 | 2017 | 391 | 0.120 |
Why?
| | Apoptosis | 4 | 2018 | 2551 | 0.120 |
Why?
| | Interferon Type I | 4 | 1994 | 141 | 0.120 |
Why?
| | Lung Neoplasms | 7 | 2016 | 2525 | 0.120 |
Why?
| | Lentigo | 1 | 2015 | 6 | 0.120 |
Why?
| | Aldehyde Dehydrogenase | 2 | 2014 | 100 | 0.120 |
Why?
| | Cell Cycle | 3 | 2010 | 598 | 0.120 |
Why?
| | Antigens, Neoplasm | 5 | 2005 | 317 | 0.120 |
Why?
| | Brain Neoplasms | 4 | 1994 | 1266 | 0.120 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 5 | 2011 | 978 | 0.120 |
Why?
| | Proportional Hazards Models | 1 | 2019 | 1272 | 0.120 |
Why?
| | Radiography | 1 | 2017 | 844 | 0.120 |
Why?
| | Neoplastic Cells, Circulating | 2 | 2006 | 79 | 0.120 |
Why?
| | Leukocyte Count | 20 | 1988 | 320 | 0.110 |
Why?
| | Myeloproliferative Disorders | 1 | 1995 | 27 | 0.110 |
Why?
| | Fenretinide | 1 | 2014 | 4 | 0.110 |
Why?
| | Oligopeptides | 1 | 2016 | 272 | 0.110 |
Why?
| | Head and Neck Neoplasms | 3 | 2013 | 553 | 0.110 |
Why?
| | Desiccation | 1 | 2014 | 22 | 0.110 |
Why?
| | Lymphoma | 4 | 1991 | 210 | 0.110 |
Why?
| | Survival Analysis | 6 | 2010 | 1289 | 0.110 |
Why?
| | Cell Division | 11 | 1998 | 790 | 0.110 |
Why?
| | Peptide Fragments | 1 | 2018 | 691 | 0.110 |
Why?
| | Cell Survival | 8 | 2018 | 1128 | 0.110 |
Why?
| | Survival Rate | 8 | 2024 | 1906 | 0.110 |
Why?
| | Peptides | 2 | 2008 | 980 | 0.110 |
Why?
| | Cohort Studies | 3 | 2024 | 5691 | 0.110 |
Why?
| | Child | 17 | 2025 | 21833 | 0.110 |
Why?
| | Perineum | 1 | 1993 | 31 | 0.100 |
Why?
| | Receptors, Estrogen | 1 | 2016 | 437 | 0.100 |
Why?
| | Basigin | 1 | 2013 | 25 | 0.100 |
Why?
| | Ear, External | 1 | 2013 | 21 | 0.100 |
Why?
| | Internet | 1 | 2018 | 674 | 0.100 |
Why?
| | Dose-Response Relationship, Drug | 7 | 2021 | 2022 | 0.100 |
Why?
| | Mohs Surgery | 1 | 2013 | 28 | 0.100 |
Why?
| | Extracellular Space | 1 | 2013 | 119 | 0.100 |
Why?
| | Matrix Metalloproteinase 9 | 1 | 2013 | 131 | 0.100 |
Why?
| | Chromosomes, Human, Pair 17 | 1 | 1992 | 55 | 0.100 |
Why?
| | Sweat Gland Neoplasms | 1 | 2012 | 7 | 0.100 |
Why?
| | Cell Proliferation | 5 | 2018 | 2467 | 0.100 |
Why?
| | In Situ Hybridization, Fluorescence | 2 | 2017 | 308 | 0.100 |
Why?
| | Chromosomes, Human, Pair 11 | 1 | 1992 | 60 | 0.100 |
Why?
| | Side-Population Cells | 1 | 2012 | 8 | 0.100 |
Why?
| | BRCA1 Protein | 1 | 2013 | 77 | 0.100 |
Why?
| | Alcohol Oxidoreductases | 1 | 2013 | 62 | 0.100 |
Why?
| | Alleles | 2 | 2022 | 886 | 0.100 |
Why?
| | Transforming Growth Factor beta1 | 1 | 2013 | 165 | 0.100 |
Why?
| | Bone Marrow Diseases | 3 | 1983 | 20 | 0.100 |
Why?
| | Vitamins | 1 | 1994 | 188 | 0.090 |
Why?
| | Decision Making | 1 | 2019 | 937 | 0.090 |
Why?
| | Ricin | 1 | 1991 | 8 | 0.090 |
Why?
| | Pyrimidinones | 2 | 2025 | 111 | 0.090 |
Why?
| | Escherichia coli Infections | 4 | 1981 | 115 | 0.090 |
Why?
| | Carcinoma, Squamous Cell | 2 | 2013 | 645 | 0.090 |
Why?
| | Sequence Analysis, DNA | 2 | 2005 | 826 | 0.090 |
Why?
| | Severity of Illness Index | 2 | 2018 | 2840 | 0.090 |
Why?
| | Peer Review | 1 | 2012 | 50 | 0.090 |
Why?
| | Malpractice | 1 | 2012 | 39 | 0.090 |
Why?
| | Immunotoxins | 1 | 1991 | 56 | 0.090 |
Why?
| | DNA Mutational Analysis | 2 | 2016 | 398 | 0.090 |
Why?
| | Phenotype | 5 | 2024 | 3150 | 0.090 |
Why?
| | Complement C1q | 1 | 2011 | 37 | 0.090 |
Why?
| | United States | 3 | 2020 | 14925 | 0.090 |
Why?
| | History, 21st Century | 1 | 2012 | 214 | 0.090 |
Why?
| | Keratinocytes | 2 | 2024 | 249 | 0.090 |
Why?
| | Immune Tolerance | 2 | 1991 | 366 | 0.080 |
Why?
| | Agranulocytosis | 6 | 1986 | 31 | 0.080 |
Why?
| | History, 20th Century | 1 | 2012 | 325 | 0.080 |
Why?
| | Pancreatitis | 1 | 1991 | 132 | 0.080 |
Why?
| | Cyclosporine | 1 | 1991 | 268 | 0.080 |
Why?
| | Blast Crisis | 1 | 1990 | 33 | 0.080 |
Why?
| | Predictive Value of Tests | 2 | 2006 | 2017 | 0.080 |
Why?
| | Time Factors | 15 | 2019 | 6818 | 0.080 |
Why?
| | Risk Assessment | 1 | 2019 | 3438 | 0.080 |
Why?
| | Neoplasms | 5 | 2018 | 2691 | 0.080 |
Why?
| | Urinary Bladder Neoplasms | 2 | 1983 | 261 | 0.080 |
Why?
| | Bacterial Infections | 4 | 1989 | 244 | 0.080 |
Why?
| | Glycoproteins | 5 | 1977 | 357 | 0.080 |
Why?
| | Vitamin E | 2 | 1994 | 123 | 0.080 |
Why?
| | Disease-Free Survival | 5 | 2019 | 672 | 0.080 |
Why?
| | Indium Radioisotopes | 1 | 1989 | 14 | 0.080 |
Why?
| | Cells, Cultured | 12 | 2019 | 4155 | 0.080 |
Why?
| | Tomography, X-Ray Computed | 2 | 2018 | 2679 | 0.080 |
Why?
| | Recombinant Proteins | 7 | 1994 | 1350 | 0.080 |
Why?
| | Transforming Growth Factor beta | 3 | 2019 | 486 | 0.080 |
Why?
| | Cell Differentiation | 7 | 2015 | 1999 | 0.080 |
Why?
| | Osteonecrosis | 2 | 1986 | 24 | 0.070 |
Why?
| | Interleukin-6 | 1 | 2013 | 785 | 0.070 |
Why?
| | Lithium | 5 | 1986 | 44 | 0.070 |
Why?
| | Neutrophils | 8 | 1988 | 1270 | 0.070 |
Why?
| | Cyclin D | 1 | 2008 | 9 | 0.070 |
Why?
| | ErbB Receptors | 2 | 2013 | 611 | 0.070 |
Why?
| | Inflammation | 1 | 2019 | 2841 | 0.070 |
Why?
| | Lymphocytes | 7 | 2006 | 391 | 0.070 |
Why?
| | Patient Safety | 1 | 2012 | 320 | 0.070 |
Why?
| | Surgical Flaps | 3 | 1986 | 141 | 0.070 |
Why?
| | Base Sequence | 2 | 2011 | 2180 | 0.070 |
Why?
| | Transcription Factors | 1 | 1996 | 1706 | 0.070 |
Why?
| | S Phase | 1 | 2008 | 77 | 0.070 |
Why?
| | Risk | 2 | 2019 | 904 | 0.070 |
Why?
| | Up-Regulation | 3 | 2019 | 843 | 0.070 |
Why?
| | Skull | 2 | 1986 | 145 | 0.070 |
Why?
| | Glucuronidase | 1 | 2007 | 43 | 0.070 |
Why?
| | Sequence Deletion | 1 | 2008 | 182 | 0.070 |
Why?
| | Receptor, Notch2 | 2 | 2020 | 15 | 0.070 |
Why?
| | Computational Biology | 3 | 2019 | 649 | 0.070 |
Why?
| | Australia | 2 | 2023 | 301 | 0.070 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2013 | 821 | 0.070 |
Why?
| | Li-Fraumeni Syndrome | 1 | 2007 | 14 | 0.070 |
Why?
| | 3' Untranslated Regions | 1 | 2008 | 145 | 0.070 |
Why?
| | Cell Movement | 5 | 2015 | 971 | 0.070 |
Why?
| | Oligosaccharides | 1 | 2007 | 59 | 0.070 |
Why?
| | Receptor, Melanocortin, Type 1 | 1 | 2007 | 7 | 0.070 |
Why?
| | Factor VIII | 1 | 1987 | 99 | 0.070 |
Why?
| | Paraneoplastic Syndromes | 1 | 2007 | 12 | 0.070 |
Why?
| | Adjuvants, Immunologic | 1 | 2008 | 238 | 0.070 |
Why?
| | Cell Self Renewal | 2 | 2017 | 56 | 0.060 |
Why?
| | Chromosome Mapping | 1 | 2008 | 514 | 0.060 |
Why?
| | Vaccinia virus | 2 | 1998 | 43 | 0.060 |
Why?
| | Disease Progression | 2 | 2013 | 2722 | 0.060 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2010 | 524 | 0.060 |
Why?
| | Myelodysplastic Syndromes | 1 | 1988 | 139 | 0.060 |
Why?
| | Education, Medical | 1 | 1990 | 271 | 0.060 |
Why?
| | Quinazolines | 1 | 2008 | 249 | 0.060 |
Why?
| | Health Education | 1 | 1990 | 355 | 0.060 |
Why?
| | Young Adult | 5 | 2025 | 13203 | 0.060 |
Why?
| | Neoadjuvant Therapy | 2 | 2006 | 407 | 0.060 |
Why?
| | Models, Biological | 4 | 2019 | 1783 | 0.060 |
Why?
| | Binding Sites | 2 | 2008 | 1316 | 0.060 |
Why?
| | Colony Count, Microbial | 1 | 2006 | 119 | 0.060 |
Why?
| | Enterobacteriaceae | 1 | 2006 | 41 | 0.060 |
Why?
| | Magnetic Resonance Imaging | 1 | 2018 | 3607 | 0.060 |
Why?
| | Vena Cava, Superior | 1 | 1985 | 22 | 0.060 |
Why?
| | Hypercalcemia | 1 | 1985 | 20 | 0.060 |
Why?
| | Fasciotomy | 1 | 1985 | 13 | 0.060 |
Why?
| | Spinal Cord Compression | 1 | 1985 | 21 | 0.060 |
Why?
| | Water Microbiology | 1 | 2006 | 85 | 0.060 |
Why?
| | Hemophilia A | 1 | 1987 | 140 | 0.060 |
Why?
| | Genome, Human | 1 | 2008 | 418 | 0.060 |
Why?
| | PTEN Phosphohydrolase | 1 | 2007 | 163 | 0.060 |
Why?
| | Viral Vaccines | 2 | 1998 | 107 | 0.060 |
Why?
| | Diphosphonates | 1 | 2006 | 69 | 0.060 |
Why?
| | Forearm Injuries | 1 | 1985 | 7 | 0.060 |
Why?
| | DNA-Binding Proteins | 1 | 2013 | 1475 | 0.060 |
Why?
| | Chromates | 1 | 1985 | 1 | 0.060 |
Why?
| | Leukocytes, Mononuclear | 1 | 2008 | 568 | 0.060 |
Why?
| | Retroperitoneal Neoplasms | 1 | 2005 | 21 | 0.060 |
Why?
| | Pruritus | 1 | 2025 | 61 | 0.060 |
Why?
| | In Vitro Techniques | 5 | 2012 | 1088 | 0.060 |
Why?
| | Chromium | 1 | 1985 | 15 | 0.060 |
Why?
| | Infant | 2 | 2019 | 9539 | 0.060 |
Why?
| | Neoplasm Invasiveness | 3 | 2018 | 498 | 0.060 |
Why?
| | Testicular Neoplasms | 2 | 1984 | 114 | 0.060 |
Why?
| | Karyotyping | 4 | 1994 | 104 | 0.060 |
Why?
| | Kidney Transplantation | 1 | 1991 | 701 | 0.060 |
Why?
| | Forearm | 1 | 1985 | 138 | 0.060 |
Why?
| | Wrist | 1 | 1985 | 56 | 0.060 |
Why?
| | Hand Injuries | 1 | 1985 | 32 | 0.060 |
Why?
| | Axilla | 1 | 2004 | 47 | 0.060 |
Why?
| | Burns, Chemical | 1 | 1985 | 33 | 0.060 |
Why?
| | Macrophages | 4 | 1988 | 1544 | 0.060 |
Why?
| | Skin Transplantation | 1 | 1985 | 85 | 0.060 |
Why?
| | Acute Disease | 6 | 1991 | 1005 | 0.060 |
Why?
| | Protein Transport | 2 | 2018 | 440 | 0.060 |
Why?
| | Ki-67 Antigen | 1 | 2004 | 109 | 0.050 |
Why?
| | Immunoenzyme Techniques | 1 | 2004 | 208 | 0.050 |
Why?
| | Blood Cell Count | 5 | 1995 | 53 | 0.050 |
Why?
| | Monocytes | 5 | 1983 | 563 | 0.050 |
Why?
| | Cyclic Nucleotide Phosphodiesterases, Type 4 | 1 | 2024 | 10 | 0.050 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2012 | 2143 | 0.050 |
Why?
| | Immunotherapy, Adoptive | 2 | 1998 | 328 | 0.050 |
Why?
| | Neoplasm Metastasis | 4 | 2007 | 670 | 0.050 |
Why?
| | Phosphorylation | 2 | 2018 | 1760 | 0.050 |
Why?
| | Azepines | 1 | 2024 | 97 | 0.050 |
Why?
| | Pregnancy Complications, Neoplastic | 1 | 2004 | 54 | 0.050 |
Why?
| | Genetic Testing | 1 | 2007 | 456 | 0.050 |
Why?
| | Pyridones | 1 | 2025 | 169 | 0.050 |
Why?
| | Urine | 4 | 1973 | 58 | 0.050 |
Why?
| | Age Distribution | 2 | 2018 | 397 | 0.050 |
Why?
| | Escherichia coli | 3 | 2006 | 826 | 0.050 |
Why?
| | Monitoring, Immunologic | 1 | 2023 | 25 | 0.050 |
Why?
| | Inhibitory Concentration 50 | 1 | 2003 | 88 | 0.050 |
Why?
| | Molecular Sequence Data | 1 | 2008 | 2924 | 0.050 |
Why?
| | Schistosoma | 1 | 1983 | 28 | 0.050 |
Why?
| | Receptors, Lysophosphatidic Acid | 1 | 2023 | 35 | 0.050 |
Why?
| | Receptors, Vascular Endothelial Growth Factor | 1 | 2003 | 107 | 0.050 |
Why?
| | Triazoles | 1 | 2024 | 155 | 0.050 |
Why?
| | Carcinoma, Transitional Cell | 1 | 1983 | 80 | 0.050 |
Why?
| | Neutropenia | 3 | 1980 | 154 | 0.050 |
Why?
| | Multiple Sclerosis | 1 | 2008 | 460 | 0.050 |
Why?
| | Protein Kinase Inhibitors | 2 | 2019 | 905 | 0.050 |
Why?
| | Immunity, Cellular | 1 | 1984 | 270 | 0.050 |
Why?
| | CTLA-4 Antigen | 1 | 2023 | 98 | 0.050 |
Why?
| | Receptors, Melanocortin | 1 | 2002 | 1 | 0.050 |
Why?
| | Receptors, Corticotropin | 1 | 2002 | 3 | 0.050 |
Why?
| | Vitamin A | 1 | 1982 | 59 | 0.050 |
Why?
| | Genes, cdc | 1 | 2002 | 11 | 0.050 |
Why?
| | Smoking | 1 | 1990 | 1597 | 0.050 |
Why?
| | Cell Lineage | 1 | 2024 | 352 | 0.050 |
Why?
| | Uveal Neoplasms | 1 | 2021 | 10 | 0.050 |
Why?
| | Cyclin-Dependent Kinase 4 | 1 | 2002 | 46 | 0.050 |
Why?
| | Wnt Signaling Pathway | 1 | 2024 | 196 | 0.050 |
Why?
| | Diskectomy | 1 | 2021 | 23 | 0.050 |
Why?
| | Neck Pain | 1 | 2021 | 26 | 0.050 |
Why?
| | Clinical Trials as Topic | 4 | 2018 | 1029 | 0.050 |
Why?
| | Clinical Trials, Phase I as Topic | 1 | 2021 | 50 | 0.050 |
Why?
| | Leukocytosis | 4 | 1974 | 31 | 0.050 |
Why?
| | Antigens | 2 | 1983 | 356 | 0.050 |
Why?
| | Gene Expression | 3 | 2008 | 1485 | 0.040 |
Why?
| | Isotretinoin | 2 | 1994 | 24 | 0.040 |
Why?
| | Incidence | 3 | 2009 | 2805 | 0.040 |
Why?
| | PAX3 Transcription Factor | 2 | 2015 | 17 | 0.040 |
Why?
| | Disease Models, Animal | 3 | 2018 | 4301 | 0.040 |
Why?
| | Paired Box Transcription Factors | 2 | 2015 | 46 | 0.040 |
Why?
| | Bone Neoplasms | 1 | 1983 | 249 | 0.040 |
Why?
| | Postoperative Period | 1 | 2022 | 347 | 0.040 |
Why?
| | Cyclin-Dependent Kinases | 1 | 2002 | 131 | 0.040 |
Why?
| | Smallpox Vaccine | 2 | 1998 | 24 | 0.040 |
Why?
| | Administration, Oral | 5 | 1995 | 785 | 0.040 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p15 | 2 | 2000 | 16 | 0.040 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2003 | 551 | 0.040 |
Why?
| | Leukemia, Lymphoid | 6 | 1979 | 27 | 0.040 |
Why?
| | Eosinophils | 1 | 1983 | 319 | 0.040 |
Why?
| | Enterobacter cloacae | 1 | 2020 | 4 | 0.040 |
Why?
| | Mycobacterium chelonae | 1 | 2020 | 9 | 0.040 |
Why?
| | Gene Amplification | 1 | 2020 | 103 | 0.040 |
Why?
| | Leukemia, Myeloid, Acute | 4 | 1984 | 632 | 0.040 |
Why?
| | Potassium Channels, Voltage-Gated | 1 | 2020 | 50 | 0.040 |
Why?
| | Tetracycline | 1 | 2000 | 14 | 0.040 |
Why?
| | Oxidoreductases | 1 | 2020 | 96 | 0.040 |
Why?
| | Tocopherols | 2 | 1994 | 26 | 0.040 |
Why?
| | Gene Dosage | 1 | 2020 | 142 | 0.040 |
Why?
| | Chromosomes, Human, 6-12 and X | 2 | 1994 | 3 | 0.040 |
Why?
| | rho GTP-Binding Proteins | 1 | 2020 | 60 | 0.040 |
Why?
| | Age Factors | 4 | 2019 | 3253 | 0.040 |
Why?
| | Quality of Life | 2 | 2022 | 2942 | 0.040 |
Why?
| | Endotoxins | 2 | 1978 | 220 | 0.040 |
Why?
| | Germ-Free Life | 1 | 1979 | 33 | 0.040 |
Why?
| | Data Curation | 1 | 2019 | 17 | 0.040 |
Why?
| | Whole Genome Sequencing | 1 | 2020 | 165 | 0.040 |
Why?
| | RNA, Messenger | 3 | 2019 | 2798 | 0.040 |
Why?
| | Enzyme Inhibitors | 1 | 2003 | 847 | 0.040 |
Why?
| | Joint Prosthesis | 1 | 2019 | 21 | 0.040 |
Why?
| | Vincristine | 3 | 1984 | 118 | 0.040 |
Why?
| | Carotenoids | 2 | 1994 | 43 | 0.040 |
Why?
| | Cyclophosphamide | 3 | 1983 | 239 | 0.040 |
Why?
| | Aneuploidy | 2 | 1994 | 88 | 0.040 |
Why?
| | Finger Injuries | 1 | 2019 | 25 | 0.040 |
Why?
| | Dysplastic Nevus Syndrome | 1 | 1998 | 2 | 0.040 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 2008 | 1104 | 0.040 |
Why?
| | Injections, Subcutaneous | 5 | 2007 | 162 | 0.040 |
Why?
| | Mast Cells | 1 | 2020 | 148 | 0.040 |
Why?
| | Azetidines | 1 | 2018 | 43 | 0.040 |
Why?
| | Erythropoietin | 3 | 1982 | 94 | 0.040 |
Why?
| | Dynamins | 1 | 2018 | 37 | 0.040 |
Why?
| | Oncostatin M | 1 | 1998 | 6 | 0.040 |
Why?
| | Arthritis | 1 | 2019 | 94 | 0.040 |
Why?
| | Prosthesis Failure | 1 | 2019 | 123 | 0.040 |
Why?
| | Echocardiography, Transesophageal | 1 | 1999 | 96 | 0.040 |
Why?
| | Heterografts | 1 | 2018 | 134 | 0.040 |
Why?
| | Chromosome Deletion | 2 | 1994 | 114 | 0.040 |
Why?
| | Membrane Glycoproteins | 1 | 2020 | 500 | 0.030 |
Why?
| | Levamisole | 1 | 1977 | 19 | 0.030 |
Why?
| | Apoptosis Regulatory Proteins | 1 | 2018 | 190 | 0.030 |
Why?
| | Drug Approval | 1 | 2018 | 87 | 0.030 |
Why?
| | Genetic Association Studies | 1 | 2019 | 373 | 0.030 |
Why?
| | Bcl-2-Like Protein 11 | 1 | 2017 | 39 | 0.030 |
Why?
| | Bone Density Conservation Agents | 1 | 2018 | 82 | 0.030 |
Why?
| | Drug Utilization | 1 | 2018 | 168 | 0.030 |
Why?
| | Sex Distribution | 1 | 2018 | 380 | 0.030 |
Why?
| | Skilled Nursing Facilities | 1 | 2018 | 141 | 0.030 |
Why?
| | Precancerous Conditions | 1 | 1998 | 166 | 0.030 |
Why?
| | Drug Evaluation | 4 | 1991 | 83 | 0.030 |
Why?
| | Felty Syndrome | 4 | 1980 | 4 | 0.030 |
Why?
| | Gene Knockout Techniques | 1 | 2017 | 118 | 0.030 |
Why?
| | Consensus | 1 | 2020 | 673 | 0.030 |
Why?
| | Range of Motion, Articular | 1 | 2019 | 407 | 0.030 |
Why?
| | Pharmacogenetics | 1 | 2018 | 165 | 0.030 |
Why?
| | Genes, p53 | 1 | 1997 | 70 | 0.030 |
Why?
| | Thioguanine | 2 | 1984 | 19 | 0.030 |
Why?
| | Carmustine | 3 | 1986 | 51 | 0.030 |
Why?
| | CD146 Antigen | 1 | 2016 | 42 | 0.030 |
Why?
| | Cytarabine | 2 | 1984 | 60 | 0.030 |
Why?
| | MCF-7 Cells | 1 | 2016 | 123 | 0.030 |
Why?
| | Menopause | 2 | 2006 | 326 | 0.030 |
Why?
| | Cicatrix | 1 | 1997 | 66 | 0.030 |
Why?
| | Thrombocytopenia | 4 | 2007 | 198 | 0.030 |
Why?
| | Amyloid Precursor Protein Secretases | 1 | 2016 | 79 | 0.030 |
Why?
| | Splenomegaly | 2 | 1995 | 15 | 0.030 |
Why?
| | Hodgkin Disease | 4 | 1985 | 139 | 0.030 |
Why?
| | Vinblastine | 2 | 2006 | 70 | 0.030 |
Why?
| | Combined Modality Therapy | 3 | 1998 | 1226 | 0.030 |
Why?
| | Cancer Vaccines | 1 | 1997 | 165 | 0.030 |
Why?
| | Anesthesia | 1 | 2018 | 192 | 0.030 |
Why?
| | Drug Administration Schedule | 4 | 2007 | 755 | 0.030 |
Why?
| | Interleukin-2 | 3 | 2006 | 451 | 0.030 |
Why?
| | Prostatic Neoplasms | 1 | 2003 | 1049 | 0.030 |
Why?
| | Antineoplastic Agents, Hormonal | 1 | 2016 | 168 | 0.030 |
Why?
| | Mercaptopurine | 2 | 1972 | 15 | 0.030 |
Why?
| | Lymphatic Diseases | 1 | 1995 | 22 | 0.030 |
Why?
| | Gene Deletion | 1 | 1997 | 390 | 0.030 |
Why?
| | DNA Copy Number Variations | 1 | 2016 | 178 | 0.030 |
Why?
| | Veins | 1 | 1995 | 65 | 0.030 |
Why?
| | Intramolecular Oxidoreductases | 1 | 2015 | 68 | 0.030 |
Why?
| | Polycythemia Vera | 1 | 1974 | 12 | 0.030 |
Why?
| | Infusions, Intravenous | 2 | 1995 | 399 | 0.030 |
Why?
| | Primary Myelofibrosis | 1 | 1974 | 10 | 0.030 |
Why?
| | Protein Binding | 2 | 2018 | 2232 | 0.030 |
Why?
| | Retinoids | 1 | 2014 | 34 | 0.030 |
Why?
| | Genetic Linkage | 1 | 2015 | 292 | 0.030 |
Why?
| | Inpatients | 1 | 2018 | 493 | 0.030 |
Why?
| | Culture Techniques | 4 | 1979 | 73 | 0.030 |
Why?
| | Surgeons | 1 | 2018 | 306 | 0.030 |
Why?
| | Random Allocation | 3 | 1990 | 360 | 0.030 |
Why?
| | Proteinuria | 1 | 1974 | 97 | 0.030 |
Why?
| | Chromosomes, Human, 16-18 | 1 | 1994 | 3 | 0.030 |
Why?
| | Chromosomes, Human, Pair 13 | 1 | 1994 | 15 | 0.030 |
Why?
| | beta Carotene | 1 | 1994 | 21 | 0.030 |
Why?
| | Chromosomes, Human, Pair 5 | 1 | 1994 | 30 | 0.030 |
Why?
| | Chromosomes, Human, Pair 3 | 1 | 1994 | 48 | 0.030 |
Why?
| | Vaginal Neoplasms | 1 | 1993 | 18 | 0.030 |
Why?
| | Vulvar Neoplasms | 1 | 1993 | 14 | 0.030 |
Why?
| | Vitamin B 12 | 1 | 1974 | 126 | 0.030 |
Why?
| | Chromosomes, Human, Pair 21 | 1 | 1994 | 42 | 0.030 |
Why?
| | Catheterization, Central Venous | 1 | 1995 | 113 | 0.030 |
Why?
| | Estrogens | 1 | 2016 | 368 | 0.030 |
Why?
| | Anus Neoplasms | 1 | 1993 | 34 | 0.030 |
Why?
| | Administration, Intranasal | 3 | 1989 | 89 | 0.030 |
Why?
| | Translocation, Genetic | 1 | 1994 | 106 | 0.030 |
Why?
| | Gonanes | 1 | 2013 | 27 | 0.030 |
Why?
| | In Situ Hybridization | 1 | 1994 | 318 | 0.030 |
Why?
| | Drug Screening Assays, Antitumor | 1 | 1994 | 193 | 0.030 |
Why?
| | Feedback, Physiological | 1 | 2013 | 79 | 0.030 |
Why?
| | Pilot Projects | 1 | 2018 | 1742 | 0.030 |
Why?
| | Specimen Handling | 1 | 2014 | 181 | 0.020 |
Why?
| | Alphapapillomavirus | 1 | 2013 | 39 | 0.020 |
Why?
| | Receptor, Notch1 | 1 | 2013 | 64 | 0.020 |
Why?
| | Retinal Dehydrogenase | 1 | 2012 | 29 | 0.020 |
Why?
| | Anemia, Aplastic | 3 | 1983 | 42 | 0.020 |
Why?
| | Aldehyde Oxidoreductases | 1 | 2012 | 27 | 0.020 |
Why?
| | Cetuximab | 1 | 2013 | 98 | 0.020 |
Why?
| | Mechlorethamine | 3 | 1982 | 59 | 0.020 |
Why?
| | Phenytoin | 2 | 1962 | 20 | 0.020 |
Why?
| | Pathology, Clinical | 1 | 2012 | 29 | 0.020 |
Why?
| | Tumor Microenvironment | 1 | 2016 | 668 | 0.020 |
Why?
| | Individuality | 1 | 1994 | 158 | 0.020 |
Why?
| | Ascorbic Acid | 1 | 1994 | 178 | 0.020 |
Why?
| | Epithelial Cells | 1 | 1998 | 1100 | 0.020 |
Why?
| | Iron | 3 | 1989 | 323 | 0.020 |
Why?
| | Patient Discharge | 1 | 2018 | 901 | 0.020 |
Why?
| | Benzoates | 1 | 1972 | 45 | 0.020 |
Why?
| | Rectal Neoplasms | 1 | 1993 | 143 | 0.020 |
Why?
| | Response Elements | 1 | 2012 | 90 | 0.020 |
Why?
| | Neoplasm Transplantation | 1 | 2012 | 250 | 0.020 |
Why?
| | Flow Cytometry | 3 | 2008 | 1193 | 0.020 |
Why?
| | Coloring Agents | 1 | 2012 | 87 | 0.020 |
Why?
| | Vaccines | 1 | 1997 | 402 | 0.020 |
Why?
| | Precision Medicine | 1 | 2016 | 419 | 0.020 |
Why?
| | Hawaii | 1 | 1991 | 36 | 0.020 |
Why?
| | Isoenzymes | 1 | 2012 | 303 | 0.020 |
Why?
| | Mice, SCID | 1 | 2012 | 368 | 0.020 |
Why?
| | Gene Silencing | 1 | 2012 | 197 | 0.020 |
Why?
| | Mitosis | 1 | 1992 | 191 | 0.020 |
Why?
| | Prednisone | 1 | 1972 | 216 | 0.020 |
Why?
| | Sodium | 2 | 1962 | 197 | 0.020 |
Why?
| | Melphalan | 3 | 1986 | 35 | 0.020 |
Why?
| | 9,10-Dimethyl-1,2-benzanthracene | 1 | 2010 | 24 | 0.020 |
Why?
| | Interleukin-8 | 1 | 2012 | 271 | 0.020 |
Why?
| | Paclitaxel | 1 | 2012 | 235 | 0.020 |
Why?
| | Bacteria | 1 | 1977 | 867 | 0.020 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2013 | 369 | 0.020 |
Why?
| | DNA Repair | 1 | 2013 | 231 | 0.020 |
Why?
| | Mice, Inbred C57BL | 4 | 2010 | 5764 | 0.020 |
Why?
| | Dermatology | 1 | 2012 | 121 | 0.020 |
Why?
| | Mice, Inbred NOD | 1 | 2012 | 596 | 0.020 |
Why?
| | Sex Ratio | 1 | 1990 | 15 | 0.020 |
Why?
| | Pigmentation | 1 | 2010 | 50 | 0.020 |
Why?
| | Megakaryocytes | 2 | 1981 | 35 | 0.020 |
Why?
| | Blotting, Western | 1 | 2013 | 1221 | 0.020 |
Why?
| | Hepatectomy | 2 | 1962 | 236 | 0.020 |
Why?
| | Staining and Labeling | 1 | 2010 | 155 | 0.020 |
Why?
| | DNA Primers | 1 | 2011 | 508 | 0.020 |
Why?
| | RNA, Small Interfering | 1 | 2012 | 619 | 0.020 |
Why?
| | California | 1 | 1991 | 440 | 0.020 |
Why?
| | DNA Damage | 1 | 2013 | 422 | 0.020 |
Why?
| | Penicillin V | 1 | 1989 | 3 | 0.020 |
Why?
| | Body Surface Area | 1 | 2009 | 34 | 0.020 |
Why?
| | Circadian Rhythm | 1 | 1994 | 476 | 0.020 |
Why?
| | Imidazoles | 1 | 2010 | 238 | 0.020 |
Why?
| | Deferoxamine | 1 | 1989 | 26 | 0.020 |
Why?
| | Diagnosis, Differential | 2 | 2012 | 1488 | 0.020 |
Why?
| | Ubiquitin-Protein Ligases | 1 | 2010 | 175 | 0.020 |
Why?
| | Lithium Chloride | 2 | 1986 | 12 | 0.020 |
Why?
| | Radionuclide Imaging | 1 | 1989 | 115 | 0.020 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2011 | 757 | 0.020 |
Why?
| | Mouth | 1 | 1989 | 87 | 0.020 |
Why?
| | Bone Regeneration | 2 | 1986 | 26 | 0.020 |
Why?
| | Interferon beta-1a | 1 | 2008 | 12 | 0.020 |
Why?
| | Cellular Senescence | 1 | 2010 | 190 | 0.020 |
Why?
| | Glatiramer Acetate | 1 | 2008 | 18 | 0.020 |
Why?
| | Abdomen | 1 | 2009 | 128 | 0.020 |
Why?
| | Eye Color | 1 | 1988 | 3 | 0.020 |
Why?
| | Anemia | 2 | 1982 | 172 | 0.020 |
Why?
| | Colorado | 2 | 2009 | 4515 | 0.020 |
Why?
| | Temperature | 3 | 1981 | 664 | 0.020 |
Why?
| | Upper Extremity | 1 | 2009 | 105 | 0.020 |
Why?
| | Chi-Square Distribution | 1 | 2009 | 520 | 0.020 |
Why?
| | Cimetidine | 1 | 1988 | 12 | 0.020 |
Why?
| | Interferon-beta | 1 | 2008 | 92 | 0.020 |
Why?
| | Lymphocyte Count | 1 | 2008 | 150 | 0.020 |
Why?
| | Chlorides | 2 | 1986 | 139 | 0.020 |
Why?
| | Surgical Procedures, Operative | 1 | 1971 | 260 | 0.020 |
Why?
| | Contusions | 1 | 2007 | 20 | 0.020 |
Why?
| | Nausea | 1 | 2007 | 111 | 0.020 |
Why?
| | Alanine Transaminase | 1 | 2007 | 150 | 0.020 |
Why?
| | Leukopenia | 2 | 1991 | 30 | 0.020 |
Why?
| | Molecular Weight | 2 | 1979 | 330 | 0.020 |
Why?
| | Neoplasms, Unknown Primary | 1 | 2006 | 18 | 0.020 |
Why?
| | Laparotomy | 1 | 2007 | 111 | 0.020 |
Why?
| | Enterobacter aerogenes | 1 | 2006 | 3 | 0.020 |
Why?
| | Vaccines, Combined | 2 | 1997 | 47 | 0.020 |
Why?
| | Electric Injuries | 1 | 1986 | 2 | 0.020 |
Why?
| | Hydroxyurea | 2 | 1984 | 34 | 0.020 |
Why?
| | N-Acetylgalactosaminyltransferases | 1 | 2005 | 6 | 0.020 |
Why?
| | Tomography, Emission-Computed | 1 | 1986 | 67 | 0.020 |
Why?
| | MART-1 Antigen | 1 | 2005 | 12 | 0.020 |
Why?
| | Hemoglobins | 1 | 1988 | 352 | 0.020 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2008 | 851 | 0.020 |
Why?
| | Metaproterenol | 1 | 1985 | 1 | 0.010 |
Why?
| | Prospective Studies | 4 | 2005 | 7580 | 0.010 |
Why?
| | Double-Blind Method | 3 | 1998 | 1921 | 0.010 |
Why?
| | Culture Media | 4 | 1977 | 163 | 0.010 |
Why?
| | Liver Neoplasms | 2 | 2006 | 762 | 0.010 |
Why?
| | Reference Standards | 1 | 2006 | 184 | 0.010 |
Why?
| | Extremities | 1 | 2006 | 135 | 0.010 |
Why?
| | Fatigue | 1 | 2007 | 336 | 0.010 |
Why?
| | Wrist Injuries | 1 | 1985 | 22 | 0.010 |
Why?
| | Neoplasm Proteins | 2 | 2005 | 429 | 0.010 |
Why?
| | Platelet Count | 2 | 1986 | 86 | 0.010 |
Why?
| | Antigens, CD | 1 | 2008 | 530 | 0.010 |
Why?
| | Edetic Acid | 1 | 1985 | 50 | 0.010 |
Why?
| | Accidents, Occupational | 1 | 1985 | 13 | 0.010 |
Why?
| | Lower Extremity | 1 | 2009 | 435 | 0.010 |
Why?
| | Kaplan-Meier Estimate | 1 | 2007 | 887 | 0.010 |
Why?
| | Erythrocytes | 3 | 1981 | 710 | 0.010 |
Why?
| | Disease Outbreaks | 1 | 1988 | 417 | 0.010 |
Why?
| | Dendritic Cells | 1 | 2008 | 491 | 0.010 |
Why?
| | Constriction, Pathologic | 1 | 1985 | 238 | 0.010 |
Why?
| | Epinephrine | 1 | 1985 | 143 | 0.010 |
Why?
| | Blood Platelets | 3 | 1974 | 421 | 0.010 |
Why?
| | Spleen | 2 | 1981 | 521 | 0.010 |
Why?
| | Syndrome | 1 | 1985 | 376 | 0.010 |
Why?
| | Nucleoproteins | 1 | 1984 | 37 | 0.010 |
Why?
| | Emergencies | 1 | 1985 | 168 | 0.010 |
Why?
| | Survivors | 1 | 2008 | 499 | 0.010 |
Why?
| | Remission Induction | 2 | 1995 | 290 | 0.010 |
Why?
| | Administration, Topical | 1 | 1984 | 145 | 0.010 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2005 | 373 | 0.010 |
Why?
| | Podophyllotoxin | 1 | 1984 | 9 | 0.010 |
Why?
| | Necrosis | 1 | 1985 | 247 | 0.010 |
Why?
| | Sex Characteristics | 1 | 2009 | 765 | 0.010 |
Why?
| | Pregnancy Trimester, Third | 1 | 2004 | 115 | 0.010 |
Why?
| | Neuropilin-1 | 1 | 2003 | 7 | 0.010 |
Why?
| | Blood Vessels | 1 | 1985 | 180 | 0.010 |
Why?
| | Liver | 2 | 1962 | 1872 | 0.010 |
Why?
| | Etoposide | 1 | 1984 | 160 | 0.010 |
Why?
| | Fibula | 1 | 1983 | 41 | 0.010 |
Why?
| | Heart Arrest | 2 | 1984 | 357 | 0.010 |
Why?
| | Cell Nucleolus | 1 | 1983 | 17 | 0.010 |
Why?
| | Enterobacter | 1 | 1983 | 8 | 0.010 |
Why?
| | Antibodies, Antinuclear | 1 | 1983 | 69 | 0.010 |
Why?
| | Busulfan | 1 | 1982 | 16 | 0.010 |
Why?
| | Klebsiella pneumoniae | 1 | 1983 | 46 | 0.010 |
Why?
| | Cell Nucleus | 2 | 1984 | 611 | 0.010 |
Why?
| | Absorption | 1 | 1982 | 60 | 0.010 |
Why?
| | Sodium, Dietary | 1 | 1962 | 39 | 0.010 |
Why?
| | Erythropoiesis | 1 | 1982 | 55 | 0.010 |
Why?
| | Bleomycin | 1 | 1984 | 248 | 0.010 |
Why?
| | Ultrasonography | 1 | 2006 | 762 | 0.010 |
Why?
| | Cytoplasm | 1 | 1983 | 267 | 0.010 |
Why?
| | Ischemia | 1 | 1985 | 408 | 0.010 |
Why?
| | Pain | 1 | 2007 | 759 | 0.010 |
Why?
| | Hypoglycemia | 1 | 2007 | 446 | 0.010 |
Why?
| | Carcinoma, Small Cell | 1 | 1982 | 171 | 0.010 |
Why?
| | Schistosomiasis | 1 | 1982 | 48 | 0.010 |
Why?
| | Transplantation, Autologous | 4 | 1984 | 242 | 0.010 |
Why?
| | Glucose | 1 | 2007 | 1032 | 0.010 |
Why?
| | Reproducibility of Results | 1 | 2009 | 3287 | 0.010 |
Why?
| | Choriocarcinoma | 1 | 1981 | 9 | 0.010 |
Why?
| | Glycogen Storage Disease Type I | 1 | 1980 | 9 | 0.010 |
Why?
| | Radiotherapy, Adjuvant | 1 | 2001 | 215 | 0.010 |
Why?
| | Biopsy | 1 | 2004 | 1089 | 0.010 |
Why?
| | Thymidine Kinase | 1 | 2000 | 15 | 0.010 |
Why?
| | Pseudomonas aeruginosa | 1 | 1983 | 347 | 0.010 |
Why?
| | Antibodies, Bacterial | 1 | 1980 | 146 | 0.010 |
Why?
| | Retinoblastoma Protein | 1 | 2000 | 56 | 0.010 |
Why?
| | Regeneration | 1 | 1962 | 198 | 0.010 |
Why?
| | Blood Transfusion | 2 | 1974 | 337 | 0.010 |
Why?
| | Doxycycline | 1 | 2000 | 60 | 0.010 |
Why?
| | Pregnancy | 2 | 2004 | 6770 | 0.010 |
Why?
| | Luciferases | 1 | 2000 | 149 | 0.010 |
Why?
| | Chromosomes, Human, 4-5 | 1 | 1979 | 2 | 0.010 |
Why?
| | Anemia, Macrocytic | 1 | 1979 | 4 | 0.010 |
Why?
| | Simplexvirus | 1 | 2000 | 82 | 0.010 |
Why?
| | Thrombocytosis | 1 | 1979 | 6 | 0.010 |
Why?
| | Electrophoresis, Cellulose Acetate | 1 | 1979 | 1 | 0.010 |
Why?
| | Pronase | 1 | 1979 | 5 | 0.010 |
Why?
| | Deoxyribonucleases | 1 | 1979 | 24 | 0.010 |
Why?
| | Ribonucleases | 1 | 1979 | 47 | 0.010 |
Why?
| | Herpesvirus 4, Human | 1 | 2000 | 165 | 0.010 |
Why?
| | Trypsin | 1 | 1979 | 76 | 0.010 |
Why?
| | Sepsis | 1 | 1985 | 601 | 0.010 |
Why?
| | Plasmids | 1 | 2000 | 359 | 0.010 |
Why?
| | Autoantibodies | 2 | 1984 | 1454 | 0.010 |
Why?
| | Remission, Spontaneous | 2 | 1977 | 40 | 0.010 |
Why?
| | Fluorescent Antibody Technique | 3 | 1984 | 384 | 0.010 |
Why?
| | Glucosephosphate Dehydrogenase | 1 | 1979 | 60 | 0.010 |
Why?
| | Hematocrit | 2 | 1977 | 102 | 0.010 |
Why?
| | Bacterial Physiological Phenomena | 1 | 1978 | 61 | 0.010 |
Why?
| | Hypocalcemia | 3 | 1984 | 27 | 0.010 |
Why?
| | Anemia, Hypochromic | 1 | 1977 | 3 | 0.010 |
Why?
| | Nitrogen | 1 | 1979 | 164 | 0.010 |
Why?
| | Transfection | 1 | 2000 | 938 | 0.010 |
Why?
| | Species Specificity | 1 | 1979 | 581 | 0.010 |
Why?
| | Staphylococcus | 1 | 1977 | 75 | 0.010 |
Why?
| | Hydrogen-Ion Concentration | 1 | 1979 | 556 | 0.010 |
Why?
| | Agar | 1 | 1977 | 11 | 0.010 |
Why?
| | Trans-Activators | 1 | 2000 | 395 | 0.010 |
Why?
| | Recombinant Fusion Proteins | 1 | 2000 | 662 | 0.010 |
Why?
| | Pneumonia | 1 | 1983 | 638 | 0.010 |
Why?
| | Arthritis, Rheumatoid | 2 | 1983 | 1156 | 0.010 |
Why?
| | Pericardium | 1 | 1976 | 55 | 0.010 |
Why?
| | Groin | 1 | 1995 | 10 | 0.010 |
Why?
| | Streptococcus pneumoniae | 1 | 1977 | 168 | 0.010 |
Why?
| | Phagocytosis | 1 | 1977 | 387 | 0.010 |
Why?
| | Subclavian Vein | 1 | 1995 | 15 | 0.010 |
Why?
| | Blood Protein Electrophoresis | 1 | 1975 | 6 | 0.010 |
Why?
| | Typhoid-Paratyphoid Vaccines | 1 | 1975 | 5 | 0.010 |
Why?
| | Pyrogens | 1 | 1975 | 55 | 0.010 |
Why?
| | Patient Compliance | 2 | 1989 | 590 | 0.010 |
Why?
| | Iron Radioisotopes | 1 | 1974 | 2 | 0.010 |
Why?
| | Cobalt Radioisotopes | 1 | 1974 | 7 | 0.010 |
Why?
| | Dialysis | 1 | 1974 | 18 | 0.010 |
Why?
| | Pyelonephritis | 1 | 1974 | 12 | 0.010 |
Why?
| | Hospitals, University | 1 | 1995 | 179 | 0.010 |
Why?
| | Centrifugation | 1 | 1974 | 27 | 0.010 |
Why?
| | Salmonella | 1 | 1975 | 63 | 0.010 |
Why?
| | Vaccines, Attenuated | 1 | 1995 | 130 | 0.010 |
Why?
| | Child, Preschool | 3 | 1985 | 11102 | 0.010 |
Why?
| | Skin Physiological Phenomena | 1 | 1994 | 25 | 0.010 |
Why?
| | Photoperiod | 1 | 1994 | 55 | 0.010 |
Why?
| | Drug Costs | 1 | 1994 | 111 | 0.010 |
Why?
| | Adrenal Gland Neoplasms | 1 | 1974 | 88 | 0.010 |
Why?
| | Virus Diseases | 1 | 1976 | 212 | 0.010 |
Why?
| | T-Lymphocytes | 1 | 1981 | 1979 | 0.010 |
Why?
| | Asthma | 1 | 1985 | 1886 | 0.010 |
Why?
| | Procarbazine | 1 | 1972 | 9 | 0.010 |
Why?
| | Hydrocortisone | 1 | 1975 | 303 | 0.010 |
Why?
| | Diseases in Twins | 1 | 1973 | 159 | 0.010 |
Why?
| | Lymphoma, Non-Hodgkin | 1 | 1972 | 84 | 0.010 |
Why?
| | Doxorubicin | 2 | 1984 | 338 | 0.010 |
Why?
| | Multiple Myeloma | 1 | 1974 | 265 | 0.010 |
Why?
| | Drug Combinations | 1 | 1972 | 343 | 0.010 |
Why?
| | Gene Expression Regulation | 1 | 2000 | 2583 | 0.010 |
Why?
| | Length of Stay | 1 | 1995 | 1210 | 0.010 |
Why?
| | Arm | 2 | 1985 | 107 | 0.000 |
Why?
| | Taurodeoxycholic Acid | 1 | 1989 | 2 | 0.000 |
Why?
| | Perfusion | 1 | 1970 | 223 | 0.000 |
Why?
| | Debridement | 1 | 1989 | 83 | 0.000 |
Why?
| | Placebos | 1 | 1989 | 196 | 0.000 |
Why?
| | Ferritins | 1 | 1989 | 67 | 0.000 |
Why?
| | Mouth Mucosa | 1 | 1989 | 91 | 0.000 |
Why?
| | Skin | 1 | 1994 | 752 | 0.000 |
Why?
| | Antibody Formation | 1 | 1970 | 298 | 0.000 |
Why?
| | Bone Marrow Examination | 2 | 1979 | 5 | 0.000 |
Why?
| | Wounds and Injuries | 1 | 1995 | 758 | 0.000 |
Why?
| | Scalp | 1 | 1986 | 35 | 0.000 |
Why?
| | Peak Expiratory Flow Rate | 1 | 1985 | 25 | 0.000 |
Why?
| | Prostaglandins E | 1 | 1985 | 49 | 0.000 |
Why?
| | Saudi Arabia | 1 | 1985 | 6 | 0.000 |
Why?
| | Lactoferrin | 1 | 1985 | 39 | 0.000 |
Why?
| | Immunodiffusion | 1 | 1984 | 14 | 0.000 |
Why?
| | Polysaccharides, Bacterial | 1 | 1985 | 68 | 0.000 |
Why?
| | Proliferating Cell Nuclear Antigen | 1 | 1984 | 50 | 0.000 |
Why?
| | Angiography | 1 | 1985 | 209 | 0.000 |
Why?
| | Antigen-Antibody Complex | 1 | 1984 | 87 | 0.000 |
Why?
| | Aerosols | 1 | 1985 | 178 | 0.000 |
Why?
| | Teniposide | 1 | 1984 | 3 | 0.000 |
Why?
| | Chromosomes, Human, 21-22 and Y | 1 | 1984 | 3 | 0.000 |
Why?
| | Tissue Preservation | 1 | 1984 | 12 | 0.000 |
Why?
| | Daunorubicin | 1 | 1984 | 24 | 0.000 |
Why?
| | Melanoma-Specific Antigens | 1 | 1983 | 5 | 0.000 |
Why?
| | False Negative Reactions | 1 | 1983 | 55 | 0.000 |
Why?
| | Postoperative Complications | 1 | 1995 | 2665 | 0.000 |
Why?
| | Syncope | 1 | 1984 | 55 | 0.000 |
Why?
| | Rats | 2 | 1962 | 5558 | 0.000 |
Why?
| | Arteries | 1 | 1985 | 261 | 0.000 |
Why?
| | Cell Line | 2 | 1983 | 2864 | 0.000 |
Why?
| | Regional Blood Flow | 1 | 1985 | 490 | 0.000 |
Why?
| | Phosphates | 1 | 1984 | 180 | 0.000 |
Why?
| | Lomustine | 1 | 1982 | 14 | 0.000 |
Why?
| | Heterozygote | 1 | 1983 | 305 | 0.000 |
Why?
| | Egypt | 1 | 1982 | 11 | 0.000 |
Why?
| | Fever | 1 | 1984 | 306 | 0.000 |
Why?
| | Heart Rate | 1 | 1985 | 785 | 0.000 |
Why?
| | Cytotoxicity, Immunologic | 1 | 1981 | 225 | 0.000 |
Why?
| | Mice, Inbred Strains | 1 | 1981 | 409 | 0.000 |
Why?
| | Tachycardia | 1 | 1981 | 55 | 0.000 |
Why?
| | Cell Separation | 1 | 1981 | 315 | 0.000 |
Why?
| | Histocompatibility Antigens Class II | 1 | 1981 | 365 | 0.000 |
Why?
| | Fanconi Anemia | 1 | 1979 | 11 | 0.000 |
Why?
| | Blood Cells | 1 | 1979 | 39 | 0.000 |
Why?
| | Complement System Proteins | 1 | 1981 | 321 | 0.000 |
Why?
| | Blood Pressure | 1 | 1985 | 1720 | 0.000 |
Why?
| | Electrocardiography | 1 | 1981 | 610 | 0.000 |
Why?
| | Cold Temperature | 1 | 1979 | 184 | 0.000 |
Why?
| | Pericardial Effusion | 1 | 1976 | 20 | 0.000 |
Why?
| | Blood | 1 | 1977 | 110 | 0.000 |
Why?
| | Autopsy | 1 | 1976 | 94 | 0.000 |
Why?
| | Cell Count | 1 | 1977 | 318 | 0.000 |
Why?
| | Kidney Failure, Chronic | 1 | 1982 | 572 | 0.000 |
Why?
| | DNA | 1 | 1983 | 1448 | 0.000 |
Why?
| | Alpha-Globulins | 1 | 1975 | 20 | 0.000 |
Why?
| | Cytogenetics | 1 | 1973 | 10 | 0.000 |
Why?
| | Recurrence | 1 | 1977 | 1073 | 0.000 |
Why?
| | Periodicity | 1 | 1973 | 58 | 0.000 |
Why?
| | Muramidase | 1 | 1973 | 81 | 0.000 |
Why?
| | Chronic Disease | 1 | 1977 | 1788 | 0.000 |
Why?
| | Leg | 1 | 1972 | 232 | 0.000 |
Why?
| | Splenectomy | 1 | 1970 | 62 | 0.000 |
Why?
| | Immunity | 1 | 1970 | 141 | 0.000 |
Why?
| | Immunization | 1 | 1970 | 405 | 0.000 |
Why?
| | Swine | 1 | 1970 | 795 | 0.000 |
Why?
| | Sheep | 1 | 1970 | 853 | 0.000 |
Why?
|
|
Robinson's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|